let's go to london and juliana tatelbaum. juliana, there are a lot of questions here state side.k-developed product and gotten a lot of attention there. we have amazing results which have come out. i see on the social media feed and people do not believe it what coverage and attention is this getting on your side of the atlantic >> reporter: brian, good morning. this is certainly getting a ton of attention over here just yesterday, i was joining to talk about the astrazeneca release of the first interim phase three results of the u.s. trial. 79% efficacy of prevent ing symptomatic covid. now you overnight, we got a statement from the national institute of allergy and infection news disease the institute headed by dr. fauci. they said astrazeneca may have included out dated trial information in the release yesterday. this was a four sentence release saying the state and monitoring board notified the institute along with barta and astrazeneca that it was concerned by information released by the company in their initial data yesterday. they expressed concern that astrazeneca may hav